Tecentriq Hybreza (atezolizumab/ hyaluronidase-tqjs)

Adult Dosing .

Dosage forms:  INJ

Special Note

[formulation clarification]

Info: nonproprietary name = atezolizumab/hyaluronidase-tqjs; not interchangeable w/ IV atezolizumab; do not substitute on a mg to mg basis

[uses, dosing may vary]

Info: refer to institution protocols and pkg insert prior to prescribing for uses and dosing incl. toxicity-related dose adjustments

non-small cell lung CA

[stage II-IIIA PD-L1-expressing dz, adjuvant tx]

Dose: 1875 mg/30,000 units SC q3wk for up to 1y; Start: after resection and platinum-based chemo

[metastatic high PD-L1-expressing dz, first-line tx]

Dose: 1875 mg/30,000 units SC q3wk; Info: for pts w/ no EGFR or ALK genomic tumor aberrations

[metastatic nonsquamous dz, first-line tx]

Dose: 1875 mg/30,000 units SC q3wk; Info: for pts w/ no EGFR or ALK genomic tumor aberrations; part of multi-drug chemo regimen

[metastatic progressive dz]

Dose: 1875 mg/30,000 units SC q3wk; Info: for pts w/ dz progression on or after platinum-containing chemo

small cell lung CA, extensive-stage

[1875 mg/30,000 units SC q3wk]

Info: part of multi-drug chemo regimen

hepatocellular CA, unresectable or metastatic

[1875 mg/30,000 units SC q3wk]

Info: use w/ bevacizumab

melanoma, unresectable or metastatic

[1875 mg/30,000 units SC q3wk]

Start: after one 28-day cycle of cobimetinib and vemurafenib; Info: for pts w/ BRAF V600 mutation; use w/ cobimetinib and vemurafenib

alveolar soft part sarcoma, unresectable or metastatic

[1875 mg/30,000 units SC q3wk]

renal dosing

[see below]

eGFR >30: no adjustment; eGFR <30: not defined

HD/PD: not defined

hepatic dosing

[see below]

mild-moderate impairment: no adjustment; severe impairment: not defined

Peds Dosing .

Peds dosing is currently unavailable or not applicable for this drug.